http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-034100-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_374bd30b140c412aedda14571cbbc4a7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 |
| filingDate | 2000-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2004-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-034100-A1 |
| titleOfInvention | USE OF A STROGEN COMPOUND FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
| abstract | Use of an estrogenic compound for the manufacture of a medicament for the treatment or prevention of postmenopausal osteoporosis which comprises starting treatment with a low dose of an estrogenic compound and, after this start period, increasing the dose of the estrogenic compound. The period of initiation of treatment commonly lasts about 4 to 8 months, preferably 6 months. After treatment, the increase in bone mineral density is greater than when treating postmenopausal osteoporosis by administering the same dose of estrogenic compound throughout the entire duration of treatment. Preferably, the low dose of an estrogenic compound used during the onset period is an equivalent dose in estrogenic activity at about 0.5 mg to 1.5 mg of estradiol valerate; and the increased dose of an estrogenic compound used during the rest of the treatment is an equivalent dose in estrogenic activity at about 1 mg to 3 mg of estradiol valerate. The preferable estrogenic compound is estradiol valerate. Other conventional estrogens such as estrone, estrone sulfate, piperazine salts of estrone sulfate and their esters, as well as synthetic estrogens can also be employed. |
| priorityDate | 1999-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.